Home › Scleroderma › District of Columbia › Washington
Scleroderma clinical trials in Washington, DC
4 studies for Scleroderma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- MedStar Georgetown University Hospital, Washington D.C.
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi away
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
RecruitingPhase 3
- Georgetown University, Washington D.C.
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RecruitingPhase 2/3
- GSK Investigational Site, Washington D.C.
Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
- Georgetown University Medical Center - Department of Rheumatology, Washington D.C.
About Scleroderma
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
More about Scleroderma on MedlinePlus
Scleroderma trials in other cities
- New York City, NY10 studies
- Ann Arbor, MI9 studies
- Houston, TX8 studies
- Chicago, IL8 studies
- Los Angeles, CA7 studies
- Boston, MA7 studies
- Durham, NC7 studies
- Baltimore, MD6 studies
- Dallas, TX5 studies
- New Orleans, LA5 studies
- Miami, FL5 studies
- Philadelphia, PA5 studies
Other studies in Washington
- Cancer (all types)60 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer44 studies
- Metastatic Cancer44 studies
- Lung Cancer41 studies
- Prostate Cancer39 studies
- Obesity34 studies
- Colorectal Cancer28 studies
- Cardiovascular Disease27 studies
- Bladder Cancer26 studies
- Ovarian Cancer25 studies
- Lymphoma23 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.